The Pharma LetterAutolus moves forward with novel CAR-T therapy candidateThe Pharma LetterUK-based immuno-oncology startup Autolus has pulled the trigger on a licensing agreement to acquire global rights from UCL Business to develop and commercialize a… Continue reading
GlobeNewswireUTHealth Receives Funding to Study Stem Cell Therapy for Traumatic InjuryNewswise (press release)Newswise — HOUSTON – (April 23, 2018) – The University of Texas Health Science Center at Houston (UTHealth) has received funding through a pub… Continue reading
Transhumanisme et intelligence artificielle (Communiqué de presse) (Blog) |
Des chercheurs utilisent CRISPR pour éditer l’ADN en dehors de la cellule
Transhumanisme et intelligence artificielle (Communiqué de presse) (Blog) Vous pouvez voir les résultats, les modifications apportées aux gènes, mais pas nécessairement comment vous y êtes arrivé, ce qui est important pour s’assurer que CRISPR puisse être utilisé en toute sécurité pour traiter les patients », a déclaré Eric … |
Drug Target Review |
CRISPR used to edit DNA outside of the cell
Drug Target Review Scientists at have developed a breakthrough CRISPR gene-editing tool, that could allow researchers to take fragments of DNA extracted from human cells, put them into a test tube, and quickly and precisely engineer multiple changes to the genetic code … Scientists use CRISPR tool to make multiple edits to DNA samples ‘in vitro’News-Medical.net Christiana Care scientists’ new approach to gene editing is a diagnostic tool for cancerDelaware First Media CRISPR And CRISPR-Associated (Cas) Genes Market Global Briefing 2018 to 2025BelAir Daily (press release) WhaTech all 6 news articles » |
|
Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay
STAT he failure of Incyte’s Phase 3 clinical trial of epacadostat combined with Keytruda, Merck’s breakthrough checkpoint inhibitor, for people newly diagnosed with melanoma was a big disappointment to the companies, the pharmaceutical industry, and … |